|
| 38019956 | Phase 1 Open-Label Dose Escalation Trial for the Development of a Human Bacillus Calmette-Guérin Challenge Model for Assessment of Tuberculosis Immunity In Vivo. | J Infect Dis | 2024 |
| 37036397 | Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical Trial. | Clin Infect Dis | 2023 |
| 37946601 | Influenza Vaccine Effectiveness Pre-pandemic among Adults Hospitalized with Congestive Heart Failure, Chronic Obstructive Pulmonary Disease, and Older Adults. | | 2023 |
| 37756530 | Relationship of Heterologous Virus Responses and Outcomes in Hospitalized COVID-19 Patients. | J Immunol | 2023 |
| 37843118 | Priorities and Progress in Gram-negative Bacterial Infection Research by the Antibacterial Resistance Leadership Group. | Clin Infect Dis | 2023 |
| 37986828 | Integrated longitudinal multi-omics study identifies immune programs associated with COVID-19 severity and mortality in 1152 hospitalized participants. | bioRxiv | 2023 |
| 37705976 | Identification of immunodominant T cell epitopes induced by natural Zika virus infection. | Front Immunol | 2023 |
| 37561027 | Immunogenicity of a 2-Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical Trial. | J Infect Dis | 2023 |
| 37698412 | Daily fosfomycin versus levofloxacin for complicated urinary tract infections. | mBio | 2023 |
| 37034641 | Immunogenicity of the BA.1 and BA.4/BA.5 SARS-CoV-2 Bivalent Boosts: Preliminary Results from the COVAIL Randomized Clinical Trial. | medRxiv | 2023 |
| 36911714 | Corrigendum: The Vacc-SeqQC project: Benchmarking RNA-Seq for clinical vaccine studies. | Front Immunol | 2023 |
| 36969241 | Therapeutic trials for long COVID-19: A call to action from the interventions taskforce of the RECOVER initiative. | Front Immunol | 2023 |
| 36966905 | Persistent SARS-CoV-2-specific immune defects in kidney transplant recipients following third mRNA vaccine dose. | Am J Transplant | 2023 |
| 37205592 | Bivalent and Monovalent SARS-CoV-2 Variant Vaccine Boosters Improve coverage of the known Antigenic Landscape: Results of the COVID-19 Variant Immunologic Landscape (COVAIL) Trial. | Res Sq | 2023 |
| 36951954 | Durability of immune responses to mRNA booster vaccination against COVID-19. | J Clin Invest | 2023 |
| 37327781 | Multi-omic longitudinal study reveals immune correlates of clinical course among hospitalized COVID-19 patients. | Cell Rep Med | 2023 |
| 36702771 | A Multicenter, Controlled Human Infection Study of Influenza A(H1N1)pdm09 in Healthy Adults. | J Infect Dis | 2023 |
| 37385888 | Modifiers of COVID-19 vaccine efficacy: Results from four COVID-19 prevention network efficacy trials. | | 2023 |
| 37376456 | Efficacy and Durability of Immune Response after Receipt of HPV Vaccines in People Living with HIV. | | 2023 |
| 36546661 | Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster. | | 2023 |
| 36689221 | Rapid Development of an Integrated Network Infrastructure to Conduct Phase 3 COVID-19 Vaccine Trials. | JAMA Netw Open | 2023 |
| 36610728 | Safety and Immunogenicity of Influenza A/H5N8 Virus Vaccine in Healthy Adults: Durability and Cross-reactivity of Antibody Responses. | Clin Infect Dis | 2023 |
| 37352211 | Researching COVID to Enhance Recovery (RECOVER) adult study protocol: Rationale, objectives, and design. | PLoS One | 2023 |
| 37104041 | Heterologous versus homologous boosting elicits qualitatively distinct, BA.5-cross-reactive T cells in transplant recipients. | JCI Insight | 2023 |
| 36725433 | Cellular and humoral immunity to Ebola Zaire glycoprotein and viral vector proteins following immunization with recombinant vesicular stomatitis virus-based Ebola vaccine (rVSVοG-ZEBOV-GP). | Vaccine | 2023 |
| 37539761 | COVID-19 Vaccination Among Patients Receiving Maintenance Renal Replacement Therapy: Immune Response, Real-World Effectiveness, and Implications for the Future. | | 2023 |
| 35137154 | Dose-Response of a Norovirus GII.2 Controlled Human Challenge Model Inoculum. | J Infect Dis | 2022 |
| 36043176 | Nucleocapsid Antigenemia in Patients Receiving Anti-CD20 Therapy With Protracted COVID-19. | Open Forum Infectious Diseases | 2022 |
| 35959208 | Clinical Features and Treatment Outcomes of Pulmonary <i>Mycobacterium avium-intracellulare</i> Complex With and Without Coinfections. | Open Forum Infect Dis | 2022 |
| 35898343 | SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses. | medRxiv | 2022 |
| 36016207 | A Framework for Inspiring COVID-19 Vaccine Confidence in African American and Latino Communities. | Vaccines | 2022 |
| 35436331 | Coronavirus Disease 2019 Vaccine Trials (and Tribulations): How to Improve the Process of Clinical Trials in a Pandemic. | Clinical Infectious Diseases | 2022 |
| 36273986 | An Oil-in-Water adjuvant significantly increased influenza A/H7N9 split virus Vaccine-Induced circulating follicular helper T (cT) cells and antibody responses. | Vaccine | 2022 |
| 35675197 | SARS-CoV-2 Evolution and Immune Escape in Immunocompromised Patients. | New England Journal of Medicine | 2022 |
| 35547849 | Safety and Immunogenicity of a Third Dose of SARS-CoV-2 mRNA Vaccine - An Interim Analysis. | | 2022 |
| 36442063 | Temporal Improvements in COVID-19 Outcomes for Hospitalized Adults: A Post Hoc Observational Study of Remdesivir Group Participants in the Adaptive COVID-19 Treatment Trial. | Ann Intern Med | 2022 |
| 36380757 | mRNA bivalent booster enhances neutralization against BA.2.75.2 and BQ.1.1. | | 2022 |
| 36482977 | Durability of immune responses to the booster mRNA vaccination against COVID-19. | medRxiv | 2022 |
| 34133889 | Fecal Microbiota Transplantation Donor Screening Updates and Research Gaps for Solid Organ Transplant Recipients. | J Clin Microbiol | 2022 |
| 35236394 | EVITA Dengue: a cluster-randomized controlled trial to EValuate the efficacy of Wolbachia-InfecTed Aedes aegypti mosquitoes in reducing the incidence of Arboviral infection in Brazil. | Trials | 2022 |
| 35037030 | Rapid Detection and Characterization of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Variant in a Returning Traveler. | Clinical Infectious Diseases | 2022 |
| 35233550 | mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant. | Cell Reports Medicine | 2022 |
| 35214748 | Racial and Ethnic Diversity in SARS-CoV-2 Vaccine Clinical Trials Conducted in the United States. | Vaccines | 2022 |
| 35214660 | Is the BCG Vaccine an Answer to Future Pandemic Preparedness? | Vaccines | 2022 |
| 35090638 | Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study. | Lancet Infect Dis | 2022 |
| 34478460 | Longitudinal analysis of human humoral responses after vaccination with a live attenuated V. cholerae vaccine. | PLoS Neglected Tropical Diseases | 2021 |
| 32198521 | Variability in the Management of Adults With Pulmonary Nontuberculous Mycobacterial Disease. | Clin Infect Dis | 2021 |
| 32152245 | Systems Biological Analysis of Immune Response to Influenza Vaccination. | Cold Spring Harb Perspect Med | 2021 |
| 34174187 | The single-cell epigenomic and transcriptional landscape of immunity to influenza vaccination. | Cell | 2021 |
| 33798491 | Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant. | | 2021 |